Research and Markets - Alzheimer's Disease Therapeutics and Diagnostics: $6.2 Billion Global Markets Forecasts to 2020
DUBLIN, April 18, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Alzheimer's Disease Therapeutics and Diagnostics: Global Markets" report to their offering.
The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.
The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (Aß) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat: mild to moderate, severe and prodromal.
Each market and its applications are analyzed, together with the regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe and Asia-Pacific. The rest of the world markets are not addressed because of their economic insignificance with respect to this report.
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Summary
Chapter 3: Overview - Alzheimer's Disease: Definition And Market Structure - Alzheimer's Disease Pathophysiology - Alzheimer's Disease Etiology - Alzheimer's Disease Epidemiology - Diagnosis And Treatment Of Alzheimer's
Chapter 4: Regulatory Landscape
- U.S. Food And Drug Administration
- European Medicines Agency
Chapter 5: Global Markets - Introduction - Market Dynamics - Global Market For Ad Therapeutics And Diagnostics
Chapter 6: North American Market For Alzheimer's Therapeutics And Diagnostics
- North American Market
Chapter 7: European Markets For Alzheimer's Therapeutics And Diagnostics - European Markets
Chapter 8: Asia-Pacific Market For Alzheimer's Therapeutics And Diagnostics
- Asia-Pacific Market
Chapter 9: Pipeline Analysis - AD Pipeline Landscape - AD Pipeline: Clinical Stage - AD Pipeline: Treatment Focus - AD Pipeline By Disease Stage - AD Pipeline: Mechanism Of Action - Major AB-Based Therapies In Clinical Trials - Major TAU-Based Therapies In Clinical Trials
Chapter 10: Companion Diagnostics
Chapter 11: Company Profiles
- AB Science
- Abbvie Inc.
- AC Immune SA
- Allergan PLC
- Affiris AG
- Amarantus Bioscience Holdings
- Anavex Life Sciences
- Astrazeneca
- Avid Radiopharmaceuticals
- Axon Neuroscience
- Axovant Sciences
- Biogen
- Boehringer Ingelheim
- Daiichi Sankyo Co
- Diagenic
- Eisai
- Eli Lilly
- F. Hoffmann La Roche AG
- GE Healthcare
- H. Lundbeck A/S
- Janssen Pharmaceuticals
- Merck & Co
- Navidea Biopharmaceuticals
- Neurotrax Corp.
- Novartis Pharma Services AG
- Ono Pharmaceutical Co.
- Otsuka Pharmaceuticals
- Pfizer Inc
- Piramal Imaging Gmbh
- Taurx Therapeutics
For more information visit
http://www.researchandmarkets.com/research/43wk5l/alzheimers
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article